SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS

SUPPRESSION OF IN-VITRO TYPE-17 RESPONSES IN SPA PATIENTS USING SMALL MOLECULE ROR-gamma T INHIBITORS

Dettagli Bibliografici
Autori principali:	De Wit, J, Al-Mossawi, M, Huhn, M, Arancibia, C, Powrie, F, Bowness, P
Natura:	Journal article
Pubblicazione:	2014

Documenti analoghi

RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.
di: de Wit, J, et al.
Pubblicazione: (2015)

Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases
di: Jiuping Zeng, et al.
Pubblicazione: (2023-06-01)

BROMODOMAIN INHIBITORS REDUCE TH17-TYPE RESPONSES IN SPONDYLOARTHRITIS IN VITRO
di: Hammitzsch, A, et al.
Pubblicazione: (2014)

Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo.
di: Steven A Saenz, et al.
Pubblicazione: (2021-01-01)

Small molecule allosteric inhibitors of RORγt block Th17-dependent inflammation and associated gene expression in vivo
di: Steven A. Saenz, et al.
Pubblicazione: (2021-01-01)

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells
di: Amineh Ghaderi, et al.
Pubblicazione: (2021-08-01)

Small-Molecule RORγt Antagonists Inhibit T Helper 17 Cell Transcriptional Network by Divergent Mechanisms
di: Xiao, Sheng, et al.
Pubblicazione: (2017)

Identification of Tetraazacyclic Compounds as Novel Potent Inhibitors Antagonizing RORγt Activity and Suppressing Th17 Cell Differentiation.
di: Qingfeng Ding, et al.
Pubblicazione: (2015-01-01)

ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
di: Amineh Ghaderi, et al.
Pubblicazione: (2020-06-01)

Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.
di: Ulf Guendisch, et al.
Pubblicazione: (2017-01-01)

CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
di: Hammitzsch, A, et al.
Pubblicazione: (2015)

Immune effector cells in SpA: What are the pathways?
di: Bowness, P, et al.
Pubblicazione: (2018)

Retinoic Acid Induces Functionally Suppressive Foxp3+RORγt+ T Cells In Vitro
di: Mónica Martínez-Blanco, et al.
Pubblicazione: (2021-08-01)

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
di: Amineh Ghaderi, et al.
Pubblicazione: (2022-10-01)

The changes of expressive levels of IL-17A, STAT3, and RORγt in different invasive pulmonary aspergillosis mice
di: Xu LN, et al.
Pubblicazione: (2018-08-01)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis
di: Al-Mossawi, M, et al.
Pubblicazione: (2013)

The role of natural killer cells, gamma delta T-cells and other innate immune cells in spondyloarthritis.
di: Al-Mossawi, M, et al.
Pubblicazione: (2013)

Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer
di: Shradheya R. R. Gupta, et al.
Pubblicazione: (2023-09-01)

The therapeutic potential of ROR&gamma; modulators in the treatment of human disease
di: Chang MR, et al.
Pubblicazione: (2012-10-01)

TMP269, a small molecule inhibitor of class IIa HDAC, suppresses RABV replication in vitro
di: Juanbin Yin, et al.
Pubblicazione: (2023-12-01)

Investigating the potential role of T helper 17 cells among women experiencing overweight and obesity and their possible therapeutic targeting of the RORγt molecule
di: Renad M. Alhamawi, et al.
Pubblicazione: (2024-11-01)

Sumoylation of RORγt regulates TH17 differentiation and thymocyte development
di: Zhiheng He, et al.
Pubblicazione: (2018-11-01)

ROR1 and ROR2 expression in pancreatic cancer
di: Dongli Liu, et al.
Pubblicazione: (2021-11-01)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
di: Xiaohua Xue, et al.
Pubblicazione: (2021-05-01)

An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients
di: Helena Bassolas-Molina, et al.
Pubblicazione: (2018-10-01)

T-bet represses collagen-induced arthritis by suppressing Th17 lineage commitment through inhibition of RORγt expression and function
di: Masaru Shimizu, et al.
Pubblicazione: (2021-08-01)

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
di: Charles J. Malemud
Pubblicazione: (2010-05-01)

Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma
di: Feng Leng, et al.
Pubblicazione: (2025-01-01)

A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo
di: Seung Ho Shin, et al.
Pubblicazione: (2017-11-01)

An inhibitor of RORγ for chronic pulmonary obstructive disease treatment
di: Harshada Desai, et al.
Pubblicazione: (2022-05-01)

Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis.
di: Chen, L, et al.
Pubblicazione: (2015)

Small-Molecule Inhibitors of TIPE3 Protein Identified through Deep Learning Suppress Cancer Cell Growth In Vitro
di: Xiaodie Chen, et al.
Pubblicazione: (2024-04-01)

A selective small-molecule inhibitor of c-Met suppresses keloid fibroblast growth in vitro and in a mouse model
di: Min-Ha Choi, et al.
Pubblicazione: (2021-03-01)

Two small-molecule inhibitors of Toxoplasma gondii proliferation in vitro
di: Qian-qian Hua, et al.
Pubblicazione: (2023-04-01)

CHARACTERIZING TYPE 17 IMMUNE RESPONSES IN ANKYLOSING SPONDYLITIS
di: Al-Mossawi, H, et al.
Pubblicazione: (2013)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
di: Guilly eRebagay, et al.
Pubblicazione: (2012-04-01)

Small Molecule Inhibitors of Ceramidases
di: Essa M. Saied, et al.
Pubblicazione: (2014-06-01)

RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma
di: David Lamb, et al.
Pubblicazione: (2021-05-01)

PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
di: Fangfang Li, et al.
Pubblicazione: (2020-02-01)

SUMOylation of ROR-γt inhibits IL-17 expression and inflammation via HDAC2
di: Amir Kumar Singh, et al.
Pubblicazione: (2018-10-01)